cilia and flagella associated protein 99Genealiases: []
Q-omics provides the consensus-scored CFAP99 profile across patient tissues and cancer cell-line models. CFAP99 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CFAP99 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CFAP99 RNA expression shows 15,145 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where CFAP99 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP99 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP99 survival associations across molecular data types. CFAP99 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP99 RNA expression–survival associations across cancer types. High CFAP99 expression shows unfavorable associations in KIRC and LUSC, but favorable associations in KIRP, BRCA, ACC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CFAP99 RNA expression.
This table summarizes CFAP99 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CFAP99. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP99 shows lower tumor expression in KICH, THCA, LUSC, KIRC and COAD and higher tumor expression in BRCA. The KICH box plot shows higher CFAP99 RNA expression in normal versus tumor tissue (log2 FC = −0.601, t-test p < 0.001).
This table shows molecular features associated with CFAP99 in patient tissues and cancer cell lines. In patient samples, CFAP99 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP99 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
